U.S. flag

An official website of the United States government

NM_001943.5(DSG2):c.2510C>A (p.Ala837Asp) AND not provided

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Mar 13, 2017
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000589319.1

Allele description [Variation Report for NM_001943.5(DSG2):c.2510C>A (p.Ala837Asp)]

NM_001943.5(DSG2):c.2510C>A (p.Ala837Asp)

Genes:
DSG2-AS1:DSG2 antisense RNA 1 [Gene - HGNC]
DSG2:desmoglein 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
18q12.1
Genomic location:
Preferred name:
NM_001943.5(DSG2):c.2510C>A (p.Ala837Asp)
HGVS:
  • NC_000018.10:g.31545896C>A
  • NG_007072.3:g.52655C>A
  • NM_001943.5:c.2510C>AMANE SELECT
  • NP_001934.2:p.Ala837Asp
  • LRG_397t1:c.2510C>A
  • LRG_397:g.52655C>A
  • NC_000018.9:g.29125859C>A
  • NM_001943.3:c.2510C>A
  • NM_001943.4:c.2510C>A
  • NR_045216.1:n.1356G>T
Protein change:
A837D
Links:
dbSNP: rs756338201
NCBI 1000 Genomes Browser:
rs756338201
Molecular consequence:
  • NM_001943.5:c.2510C>A - missense variant - [Sequence Ontology: SO:0001583]
  • NR_045216.1:n.1356G>T - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000697886Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Uncertain significance
(Mar 13, 2017)
germlineclinical testing

LabCorp Variant Classification Summary - May 2015.docx

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV000697886.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

Variant summary: The DSG2 c.2510C>A (p.Ala837Asp) variant located in the Catenin binding domain (via InterPro) involves the alteration of a conserved nucleotide that 4/4 in silico tools (SNPs&GO not captured due to low reliability index) predict a damaging outcome, although these predictions have yet to be functionally assessed. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 3/120474 (1/40160), which does exceed the estimated maximal expected allele frequency for a pathogenic DSG2 variant of 1/100000, suggesting this variant could be a rare benign polymorphism. However, this observation needs to be cautiously considered due to the cohort containing individuals that could harbor a DSG2 phenotype. The variant of interest has not, to our knowledge, been reported in affected individuals via publications and/or reputable databases/clinical diagnostic laboratories. Therefore, until additional information becomes available (ie, clinical and functional studies), the variant of interest has been classified as a "Variant of Uncertain Significance - Possibly Benign (VUS)."

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 7, 2024